Table 3. Subsequent anti-neoplastic and endocrine therapies.
| Type of treatment | PREVAIL (n=1,717) [6] | PREVAIL Korean (n=78) [10] | Current study (n=199) | ||
|---|---|---|---|---|---|
| ENZA (n=872) | Placebo (n=845) | ENZA (n=40) | Placebo (n=38) | ||
| Any systemic treatment | 382 (43.8) | 642 (76.0) | 7 (17.5) | 25 (65.8) | 70 (35.2) |
| Missing | 23 | ||||
| Antineoplastic agent | 308 (35.3) | 515 (60.9) | 6 (15.0) | 22 (57.9) | 40 (22.7) |
| Docetaxel | 286 (32.8) | 479 (56.7) | 5 (12.5) | 22 (57.9) | 34 (19.3) |
| Abiraterone acetate | 179 (20.5) | 385 (45.6) | 1 (2.5) | 4 (10.5) | 9 (5.1) |
| Cabazitaxel | 51 (5.8) | 110 (13.0) | 0 (0.0) | 3 (7.9) | 2 (1.1) |
| Mitoxantrone | 5 (0.6) | 9 (1.1) | 0 (0.0) | 1 (2.6) | 0 (0.0) |
Duplicated count was allowed.
ENZA, enzalutamide.